Hck-IN-1

Hck-IN-1 (compound B9), a diphenylpyrazolo compound, is a selective Nef-dependent Hck inhibitor with IC50s of 2.8 μM, >20 μM for Nef:Hck complex and Hck, respectively. Hck-IN-1 is a direct and wide HIV-1 Nef antagonists with an IC50 of 100-300 nM for wild-type HIV-1 replication. Hck-IN-1 binds pocket residue Asn126 and has anti-retroviral activity[1].

Product Specifications

CAS Number

[1473404-51-1]

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

HIV; Src

Type

Reference compound

Related Pathways

Anti-infection; Protein Tyrosine Kinase/RTK

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/hck-in-1.html

Concentration

10mM

Purity

98.10

Solubility

DMSO : 12.5 mg/mL (ultrasonic)

Smiles

S=C(N1N=C(C2=CC=C([N+]([O-])=O)C=C2)C(/N=N/C3=CC=CC(Cl)=C3)=C1O)N

Molecular Formula

C16H11ClN6O3S

Molecular Weight

402.81

Precautions

H315, H319, H320

References & Citations

[1]Emert-Sedlak LA, et al. Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity. Chem Biol. 2013 Jan 24;20 (1) :82-91.